PRRT2 and melanoma: The elevated levels of SAG observed in the tumors might potentiate this signaling cascade through PKC activation and enhanced RasGRP1 activation, thereby ensuring persistent and amplified MAPK/ERK pathway activation, thus promoting melanoma progression.